StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Kush Bohra

BUYEmcure Pharmaceuticals Limited

byKush BohraHorizon: NA (inferred Swing (≤2wk))10 Aug 2026via NDTV Profit (Live)

Entry₹2,005Inferred
Target₹2,135
Total upside +6.48% (call closed)
Stop loss₹1,915-4.49% risk
Exit₹1,91517 Aug 2026, 9:15 am
Stop-loss hit-4.49%
Follow Kush Bohra for new calls(41% target hit, 88 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 99 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 17 Aug 2026
4 supporting1 neutral0 opposing
Supports the BUY call (4)

Emcure Pharma receives USFDA EIR for Sanand facility; regulator classifies it as 'VAI'; here's what it means

NewsCnbc-Tv18·8 Aug · 1w ago

(opens in new tab)

Emcure Pharmaceuticals Q1 Results: Net profit rises 42%, international business aids topline growth

NewsCnbc-Tv18·6 Aug · 1w ago

(opens in new tab)

Emcure Pharma Q1: Net Profit Jumps 42%; CEO Satish Mehta Appointed As Chairman

NewsNdtv-Profit·6 Aug · 1w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·8 Jul · 1mo ago

Neutral / worth noting (1)

Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·6 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.